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Abstract
Background: Treatment of schizophrenia and major depressive disorder (MDD) with atypical antipsychotics (AAPs)
show improved efficacy and reduced side effect burden compared with older antipsychotic medications. However,
a risk of treatment-emergent adverse events (TEAEs) remains. TEAEs are hard to quantify and perspectives on the
importance of TEAEs differ across patients and between patients and physicians. The current study is a qualitative
assessment that investigates TEAEs of AAPs from both patient and physician perspectives to provide better
understanding of the occurrence and burden of TEAEs associated with these medications.
Methods: Focus groups comprised of patients with MDD and interviews with patients with schizophrenia were
conducted at two qualitative research facilities, along with a physician focus group at one of the facilities.
Information collected from patients included an exhaustive list of TEAEs experienced, and the frequency and level
of bother of each TEAE; from psychiatrists, information included an exhaustive list of TEAEs based on personal
observations and patient report, frequency of TEAEs, clinically important TEAEs, and levels of patient-perceived
bother. Standard qualitative analysis methods were used to identify, quantify, characterize, and summarize patterns
found in the data collected.
Results: A total of 42 patients (25 with MDD and 17 with schizophrenia) and 4 psychiatrists participated in the
study. TEAEs reported as bothersome across both patients groups included cognitive issues, weight gain and/or
increased appetite, low energy, extrapyramidal symptoms (EPS), and need to sleep/excessive sleep/excessive
sleepiness. TEAEs considered more bothersome by patients with schizophrenia were weight gain, low energy, EPS,
mental anxiety, and increased positive symptoms; those considered more bothersome by patients with MDD were
cognitive issues, somnolence/sedation, and flat/restricted affect. TEAEs considered most clinically important by
psychiatrists included metabolic syndrome, weight gain, neutropenia, hyperglycemia, and QT prolongation; those
TEAEs considered most bothersome to patients from physicians’ perspectives included weight gain, reduced sexual
desire or performance, EPS, akathisia, and hormonal issues.
Conclusions: The wide range of TEAEs that are both frequent and bothersome and the variation in perceived
burden according to diagnosis highlight the need for a tailored TEAE-awareness approach when choosing an AAP.
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Background
Atypical antipsychotics (AAPs) are an effective treat-
ment for many types of mental illnesses. According to
treatment guidelines, antipsychotics are recommended
for schizophrenia treatment [1–3], for the treatment of
bipolar disorders [4, 5], and in some cases, as adjunct
therapy for major depressive disorder (MDD) [6, 7].
Although effective, AAPs are often associated with
treatment-emergent adverse events (TEAEs), which can
be highly burdensome and can affect quality of life and
medication adherence [8–10]. Accordingly, treatment
guidelines recommend that physicians modify treat-
ment regimens based on patients’ response and ability
to tolerate side effects [1–7]. This report focused on
schizophrenia and MDD as two groups that could be
anticipated to experience the effects of the medication
very differently, as it was important to study the scope
of how patients experience TEAEs. In recent decades,
AAPs have been introduced for the treatment of schizo-
phrenia and MDD, with both improved treatment effi-
cacy and reduced neurological side effect burden
compared with older, first generation antipsychotics
[11, 12]. Schizophrenia affected an estimated 1.1% of
adults (2.6 million) in the United States in 2013, and
onset in early adulthood is common, often leading to
chronic lifelong disability [13, 14]. MDD is even more
prevalent in the United States, with an estimated 6.7%
(15.7 million) adults having experienced an MDD epi-
sode in 2013, and more than 10 million who received
treatment for depression [15]. However, despite the im-
proved efficacy and tolerability profiles of AAPs, the
risk of TEAEs still associated with these agents often
includes weight gain and metabolic syndrome, extrapyr-
amidal symptoms (EPS), sexual dysfunction, and sed-
ation and somnolence, depending on the specific agent
[9, 16, 17]. A multiple treatment meta-analysis of
schizophrenia trials has shown that although antipsy-
chotics had small but robust differences in efficacy, they
differed substantially in side effects [12].
Perspectives on the importance of TEAEs differ across
patients and between patients and physicians. That is,
how patients are affected by TEAEs is specific to each
individual and may also be seen differently by physicians.
These differences in perspectives and preferences must
be taken into account within the therapeutic alliance, as
they may impact treatment decisions when considering
the overall benefit-risk profile. In fact, increasing import-
ance is being placed on bringing the patients’ perspec-
tives to the evaluation of the overall benefit-risk profile
for treatment [18]. In a study reviewing adverse events
of antipsychotics as outcome measures, it was concluded
that a patient’s subjective experience of medication
should be given more consideration [19]. Although
TEAEs are an important consideration for treatment,
they are hard to quantify. The patient’s perspective may
assist in this and has been used in other disease fields.
For example, in rheumatology, a tolerability index that
has been used in clinical trials incorporates a patient-
based method of assessing TEAEs [20]. In cancer clinical
trials, a recommended core set of patient-reported symp-
toms for measuring side effects has been established to
promote consistent assessment of treatment-related symp-
toms [21]. There are a number of neuroleptic side-effect
assessment scales available [22, 23], and among the
most complete are the 48-item Udvalg for Kliniske
Undersogelser (UKU) rating scale [24] and the Liver-
pool University Neuroleptic Side-Effect Rating Scale
(LUNSERS) [25]. However, these scales do not fully
account for the patient’s subjective experience or pref-
erence. Although considered important, the differences in
patient and physician perspective in schizophrenia and
MDD appear to be lacking in the literature.
The current study investigates TEAEs of AAPs from
both patient and physician perspectives. The goal of the
study was to provide better understanding of the occur-
rence and burden of TEAEs associated with AAP medi-
cations, as reported by patients and physicians. The
initial feedback gained in this study will be used for a
future project to generate an algorithm for a tolerability
index score that will quantify the burden of AAP
TEAEs and fully accommodate patient preference
through a discrete choice experiment. The development
of this index measure to assess the burden of TEAEs
could help facilitate the prescribing of AAP medications
to individuals with MDD and schizophrenia. A first
step to establishing this potential tolerability index al-
gorithm would be to evaluate which TEAEs are most
bothersome to patients. Although the long-term goal is
to allow the approach towards assessing TEAEs to be
transnational, the patient selection was based in the
US, partly due to the push by the FDA to include pa-




To gain insight into the occurrence and burden of
TEAEs associated with AAPs, focus groups with patients
with MDD and interviews with patients with schizophre-
nia were conducted at two qualitative research facilities:
one in Raleigh, North Carolina, USA, and one in St.
Louis, Missouri, USA. Although focus groups are more
efficient in terms of the time required for data collection
and appropriate for data collection in the MDD patient
population, previous studies have demonstrated that
individual interviews are more successful in obtaining
adequate feedback from individuals with schizophre-
nia, as these patients are generally more comfortable
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discussing their symptoms and experiences on an indi-
vidual basis [26]. A physician focus group was also
conducted with psychiatrists at the North Carolina lo-
cation to obtain their perspectives on the occurrence
and importance of TEAEs in these patient popula-
tions. This study fully adhered to COREQ guidelines
and methodology. Medical recruiters at each facility
screened all participants following a study review by
an institutional review board (RTI IRB Approval 2/18/
15; # 13733); informed, written consent was obtained
prior to initiation of the study. Patients and physicians
were provided an honorarium in appreciation for their
time.
Physician and patient recruitment
Patients were selected from the individual site databases
of general community residents who had previously
agreed to be contacted for potential research opportun-
ities. Patients were identified and screened, based on
their own reports, to meet the inclusion criteria of being
an English-speaking adult with a clinician-administered
diagnosis of MDD or schizophrenia, taking one or more
AAPs within the past year, and reporting one or more
TEAEs associated with an AAP. The AAPs included
were: aripiprazole, asenapine, clozapine, iloperidone,
lurasidone, olanzapine, paliperidone, quetiapine, risper-
idone, or ziprasidone. Physicians interested in partici-
pating in the study were identified from the North
Carolina site database. Each physician was selected by
meeting the criteria of being a practicing psychiatrist
providing direct care of adult patients with MDD and/
or schizophrenia and regular treatment of these pa-
tients with AAP medication (e.g., 10% or more of pa-
tients with MDD requiring adjunctive therapy).
Procedures
In this study, a TEAE was defined as “any untoward or
undesirable medical occurrence in a patient that was
linked in time with the use of a pharmaceutical/medi-
cinal product and that may or may not be considered to
be related to that product.” Adverse drug events were
not actively solicited, ascertained, or evaluated in the
study; however, because this project was conducted by
Lundbeck, if a potential TEAE associated with a Lundbeck
product became evident through the conduct of this quali-
tative research, a TEAE report was submitted to Lundbeck
US Pharmacovigilance.
Semi-structured interview guides were utilized to
provide structure to the MDD focus groups (lasting ap-
proximately 1.5 h each), the schizophrenia individual
interviews (lasting 45 min each), and the psychiatrist
focus group (lasting approximately 1.5 h). All focus
groups and interviews were conducted by two PhD-
level psychologists. General discussion was followed by
targeted questions along with handouts for each partici-
pant to provide individualized feedback. The following
information was obtained at the group or individual pa-
tient level: 1) exhaustive lists of TEAEs experienced, 2)
frequency of each TEAE, and 3) bother ranking for the
most bothersome TEAEs (“1” for most bothersome
TEAE, “2” for the next most bothersome, and so on; up
to a number that seemed meaningful to the patient). At
the physician level, collected information included: 1)
an exhaustive list of TEAEs observed or reported by
their patients; 2) the most and least frequently occur-
ring TEAEs; 3) clinically important TEAEs (ranked as
1 for most clinically important); and 4) level of
patient-perceived bother for each clinically important
TEAE (0 = no bother to 10 = extremely bothered). Phy-
sicians were not asked to distinguish between adverse
event profiles for patients with MDD and schizophrenia.
Analysis
To ensure consistency in organizing and coding TEAEs
across patients and physicians, a codebook was devel-
oped and applied, providing consensus in TEAE coding
decisions by each of the two focus group and interview
moderators.
In order to organize the rankings and rating scores in
a more meaningful manner, a “top 3 box” approach was
taken (i.e., collapsing the proportion of participants
reporting in the top 3 responses). For example, bother
and clinical importance rankings of 1, 2, and 3 were col-
lapsed into the “most” bothersome or “most” clinically-
important TEAEs, and ratings of 8, 9, and 10, among
physicians in rating patient burden were collapsed into
the “most” bothersome to patients. Given the qualitative




A total of 42 patients participated in the study—25 pa-
tients with MDD and 17 with schizophrenia (Table 1).
More than half of the patients with MDD were female
(64%) and more than half of the patients with schizo-
phrenia were male (65%). The most common currently
prescribed AAPs in patients with MDD were quetiapine
and aripiprazole (both 24%) and for patients with schizo-
phrenia, risperidone and olanzapine (both 24%). These
AAPs were also the most commonly prescribed to each
of the two patient groups within the last year. Of pa-
tients with MDD, 44% were diagnosed within the last
10 years while 35% of patients with schizophrenia were
diagnosed within that time frame. Of patients with
MDD, 48% reported living with a spouse or partner
while only 4% reported living with roommates who were
not family members. Patients with schizophrenia more
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often reported living with non-family roommates (29%)
than living with a spouse or partner (24%).
Four psychiatrists participated in the study; all were
male and they had an average of 21.5 years of experience
in practice. In total during the last year, the psychiatrists
treated approximately 600 patients with MDD (35% of
whom used AAPs) and approximately 300 patients with
schizophrenia (57% of whom used AAPs). All of the psy-
chiatrists regularly prescribed quetiapine, aripiprazole,
risperidone, olanzapine, lurasidone, and ziprasidone;
75% of them regularly prescribed clozapine and paliperi-
done; and 50.0% regularly prescribed asenapine.
Patient results
During the MDD group discussions and the schizophre-
nia interviews, exhaustive lists of TEAEs were devel-
oped. The first step was to gather a list of AEs from the
patients via spontaneous elicitation, followed by queries
to the patients from a target listing of TEAEs. Specific
TEAEs reported by more than half of patients overall
(across both patient types) included: weight gain (76%),
cognitive issues including decreased ability to attend,
concentrate, remember, or recall (79%), need to sleep/
excessive sleep/excessive sleepiness (71%), low energy
(67%), EPS (62%), and anxiety (55%) (Tables 2 and 3).
The reporting rates of the TEAEs differed between the
two groups of patients. For example, patients with MDD
were most likely to report cognitive issues as a TEAE
(92%) while patients with schizophrenia were most likely
to report weight gain as a TEAE (94%). Patients with
MDD also commonly reported somnolence (76%),
weight gain (64%), low energy (56%), and EPS (52%).
Along with weight gain, patients with schizophrenia
commonly reported low energy (82%), EPS (77%), som-
nolence/sedation (71%), and anxiety (65%).
Using the exhaustive list of TEAEs generated in each
group or interview as a reference guide, patients re-
ported those that they perceived as bothersome and, of
those, further delineated the TEAEs they found to be
“most bothersome” through a ranking process. Table 2
lists the frequencies of TEAEs reported by patients with
MDD as well as those identified as bothersome and the
bothersome TEAEs ranked as the top 3 “most bother-
some”. Table 3 lists the frequencies of TEAEs reported
by patients with schizophrenia. The table includes the
TEAEs identified as bothersome, as well as those ranked
in the top 3 “most bothersome.” Specific TEAEs re-
ported as bothersome across the overall patient sample
(across both patient groups) included cognitive issues
(57%), weight gain and/or increased appetite (55%), low
energy (48%), EPS (36%), and need to sleep/excessive
sleep/excessive sleepiness (36%). Again, the pattern of
results differed between the two patient groups. Patients
with MDD were most likely to include cognitive issues,
weight gain, and excessive sleepiness as bothersome is-
sues (72, 44, and 36%, respectively). These same three
TEAEs were also most likely to be selected as most
bothersome by patients with MDD (52, 32, and 28% of
patients, respectively) although the TEAE of low energy
was also rated as most bothersome 28% of the time. In
contrast, patients with schizophrenia were most likely to
include weight gain (71%), low energy (71%), and EPS
(59%) on the list of bothersome TEAEs, and then to se-
lect weight gain, low energy, and anxiety as the most
bothersome symptoms (41, 35, and 35%, respectively).
There were other findings that were common across
both patient groups. For instance, reduced sexual de-
sire was mentioned as a TEAE by 44% of patients with
MDD and by 47.1% of patients with schizophrenia;
however, neither group was likely to endorse this
TEAE as the most bothersome (8.0% for MDD and
11.8% for schizophrenia).








Male 9 (36) 11 (65) 20 (48)
Female 16 (64) 6 (35) 22 (52)
Age, years
Mean (range) 46.4 (23–70) 45.5 (25–59) 46.0 (23–70)
Race/ethnicity,a n (%)
White 20 (80) 9 (53) 29 (69)
African American 3 (12) 8 (47) 11 (26)
Asian 1 (4) 0 (0) 1 (2)
Hispanic/Latino 1 (4) 1 (6) 2 (5)
Mixed race 0 (0) 1 (6) 1 (2)
Current atypical medications,
n (%)b
Quetiapine 6 (24) 2 (12) 8 (19)
Aripiprazole 6 (24) 2 (12) 8 (19)
Risperidone 3 (12) 4 (24) 7 (17)
Olanzapine 0 (0) 4 (24) 4 (10)
Lurasidone 3 (12) 2 (12) 5 (12)
Clozapine 1 (4) 2 (12) 3 (7)
Ziprasidone 2 (8) 1 (6) 3 (7)
Paliperidone 0 (0) 1 (6) 1 (2)
Fluphenazine 0 (0) 1 (6) 1 (2)
Asenapine 0 (0) 1 (6) 1 (2)
a Participants could report more than 1 race
b Total may not equal 100%. Four patients with schizophrenia and one patient
with MDD reported using more than one AAP, and four patients with MDD
and 2 patients with schizophrenia had a recent history of AAP use but were
not currently using an AAP at screening. Each medication listed may include
reference to 1 or more brand names, the chemical or generic name, and/or
different formulations
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The burden or impact of TEAEs varied in the patient
groups, although some generalities could be made. For
example, cognitive issues were reported by both groups
of patients although patients with MDD reported a more
significant impact, including trouble holding conversa-
tions, trouble managing work or school, concern about
“losing it” or having permanent memory problems, and
having poor self-esteem resulting from “feeling stupid”.
Participants in both groups noted concerns about gain-
ing weight: small amounts gained quickly, and large
amounts gained over a longer period. Most patients at-
tributed weight gain to AAP use and patients in both
groups noted that the weight gain resulted in physical
problems, poor body image, and poor self-esteem. Add-
itionally, whereas patients with schizophrenia verbalized
that they would likely discontinue their medications be-
cause of significant weight gain and the related concern
about the impact on existing and future cardiometabolic
TEAEs, patients with MDD noted that they would rather
live with the TEAEs associated with the medications
than with extreme depressive symptoms. Both groups
also noted increased fatigue, low energy, and sleepiness,
usually immediately following AAP initiation and, espe-
cially in the case of patients with schizophrenia, these
TEAEs were noted with each administration of medica-
tion. The impact of the somnolence/sedation was signifi-
cant and similar in the two groups and included missing
Table 2 Frequency, bother, and most bothersome atypical
antipsychotic AEs reported by patients with MDD
MDD, n (%)
(n = 25)
AE Categories Frequency Bother Most
Bothersomea
Cognitive issues 23 (92) 18
(72)
13 (52)






Weight loss and/or decreased
appetite
5 (20) 0 0
Somnolence/sedation 19 (76) – –
Need to sleep/excessive
sleep/excessive sleepiness
19 (76) 9 (36) 7 (28)
Zombie-like/out of it 5 (20) 2 (8) 1 (4)
Low energy 14 (56) 8 (32) 7 (28)
EPS 13 (52) 5 (20) 3 (12)
Anxietyb 12 (48) 6 (24) 4 (16)
Mental anxiety 6 (24) 2 (8) 2 (8)
Physical anxiety 8 (32) 1 (4) 0
Social anxiety 0 0 0
Sexual function 12 (48) – –
Increased sexual desire/activities 1 (4) 1 (4) 0
Reduced sexual desire or
performance
11 (44) 5 (20) 2 (8)
Anticholinergic-related dryness 12 (48) – –
Dry eyes 3 (12) 0 0
Dry mouth 9 (36) 3 (12) 1 (4)
Dry skin 2 (8) 2 (8) 0
Disequilibrium 11 (44) 3 (12) 0
Insomnia 9 (36) 3 (12) 2 (8)
Restlessness/akathisia 9 (36) 5 (20) 2 (8)
Flat/restricted affect 8 (32) 7 (28) 6 (24)
Anger/aggression 8 (32) 5 (20) 3 (12)
Irritability 7 (28) 6 (24) 4 (16)
Depressive symptoms 6 (24) 6 (24) 4 (16)
Hypomania 5 (20) 4 (16) 2 (8)
Social withdrawal 5 (20) 2 (8) 2 (8)
Bowel/digestive system changes 5 (20) – –
Constipation 1 (4) 1 (4) 0
Diarrhea 3 (12) 1 (4) 0
Nausea/vomiting 2 (8) 0 0
Cardiovascular 4 (16) – –
Hypertension 2 (8) 1 (4) 0
Hypotension 1 (4) 0 0
QT prolongation/skipped
heartbeat
1 (4) 1 (4)
Table 2 Frequency, bother, and most bothersome atypical
antipsychotic AEs reported by patients with MDD (Continued)
Visual problems 3 (12) 2 (8) 0
Abnormal blood/laboratory
test levels
3 (12) – –
Anemia 0 0 0
Hyperglycemia 1 (4) 1 (4) 1 (4)
Hyperlipidemia 2 (8) 2 (8) 0
Hormonal 2 (8) 2 (8) 0
Pain 2 (8) 1 (4) 1 (4)
Other c 2 (8) 1 (4) 0
Major medical (hypothyroidism) 2 (8) 0 0
Major medical (diabetes) 0 0 0




Abbreviations: EPS extrapyramidal symptoms, MDD major depressive disorder,
QT time between the start of the Q wave and the end of the T wave in the
heart’s electrical cycle
a The top 5 AEs most frequently reported as most bothersome are highlighted
in bold
b Anxiety is reported as the sum of the participants who endorsed any of the
anxiety subcodes and also accounts for participants who reported “anxiety”
without noting a subcode
c The category of “other” was created to represent select symptoms reported
by 2 or fewer participants that were also not reported as most bothersome,
most clinically important, or an AE of specific interest
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time with family and friends, missing social activities,
lack of energy leading to not eating properly, poor self-
esteem, and feelings of sedation that interfered with
proper functioning. Patients in both groups reported
EPS symptoms, including tremors and irregular jerky
movements, but only patients in the schizophrenia
group reported them as burdensome and impactful. Im-
pact in these patients included the fear of others no-
ticing tremors in public and interference with job duties.
Patients in both groups noted change in sexual desire
and functioning, and while most patients who reported
this experienced decreased sexual desire effect, a few pa-
tients experienced increased desire. However, in both
cases, most patients did not report an impact.
Physician results
As a group, the physicians also participated in the cre-
ation of an exhaustive list of TEAEs. Using the exhaust-
ive list as an index, the physicians reported and then
rated or ranked both clinically important and bother-
some TEAEs (Table 4). Those considered most clinically
important by at least 2 of the 4 psychiatrists were meta-
bolic syndrome (100%), weight gain (50%), neutropenia
(75%), hyperglycemia (50%), and QT prolongation (50%).
TEAEs considered most bothersome to patients by at
least 2 of the 4 psychiatrists were weight gain (100%), re-
duced sexual desire or performance (50%), EPS (50%),
akathisia (50%), and hormonal issues (50%).
Table 3 Frequency, bother, and most bothersome atypical
antipsychotic AEs reported by patients with schizophrenia
Schizophrenia, n (%)
(n = 17)
AE Categories Frequency Bother Most
Bothersomea








4 (24) 0 0
Low energy 14 (82) 12
(71)
6 (35)
EPS 13 (77) 10 (59) 2 (12)
Somnolence/sedation 12 (71) – –
Need to sleep/excessive
sleep/excessive sleepiness
11 (65) 6 (35) 1 (6)
”Zombie-like”/”out of it” 4 (24) 2 (12) 1 (6)
Anxiety b 11 (65) 8 (47) 6 (35)
Mental anxiety 7 (41) 6 (35) 6 (35)
Physical anxiety 4 (24) 4 (24) 2 (12)
Social anxiety 1 (6) 0 1 (6)
Cognitive issues 10 (59) 6 (35) 3 (18)
Sexual function 10 (59) – –
Increased sexual desire/activities 2 (12) 1 (6) 1 (6)
Reduced sexual desire or
performance
8 (47) 4 (24) 2 (12)
Increased schizophrenia
positive symptoms
8 (47) 7 (41) 4 (24)
Anticholinergic-related dryness 7 (41) – –
Dry eyes 1 (6) 0 0
Dry mouth 6 (35) 5 (29) 3 (18)
Dry skin 0 0 0
Visual problems 7 (41) 4 (24) 2 (12)
Insomnia 6 (35) 5 (29) 2 (12)
Restlessness/akathisia 6 (35) 3 (18) 3 (18)
Disequilibrium 5 (29) 3 (18) 1 (6)
Cardiovascular 5 (29) – –
Hypertension 4 (24) 1 (6) 1 (6)
Hypotension 1 (6) 1 (6) 1 (6)
QT prolongation/skipped heartbeat 0 0 0
Depressive symptoms 4 (24) 2 (12) 2 (12)
Pain 4 (24) 2 (12) 1 (6)
Bowel/digestive system changes 4 (24) – –
Constipation 2 (12) 0 0
Diarrhea 2 (12) 1 (6) 1 (6)
Nausea/vomiting 1 (6) 1 (6) 0
Abnormal blood/laboratory
test levels
4 (24) – –
Anemia 1 (6) 1 (6) 1 (6)
Table 3 Frequency, bother, and most bothersome atypical
antipsychotic AEs reported by patients with schizophrenia
(Continued)
Hyperglycemia 1 (6) 1 (6) 0
Hyperlipidemia 2 (12) 1 (6) 1 (6)
Irritability 3 (18) 2 (12) 1 (6)
Anger/aggression 2 (12) 2 (12) 1 (6)
Hypomania 2 (12) 2 (12) 0
Hormonal 2 (12) 1 (6) 1 (6)
Otherc 2 (12) 1 (6) 0
Major medical (diabetes) 2 (12) 1 (6) 1 (6)
Major medical (seizures) 1 (6) 1 (6) 0
Flat/restricted affect 1 (6) 0 0
Social withdrawal 1 (6) 0 0
Major medical (hypothyroidism) 0 0 0
Abbreviations: EPS extrapyramidal symptoms, QT the time between the start of
the Q wave and the end of the T wave in the heart’s electrical cycle
a The top 5 AEs most frequently reported as most bothersome are highlighted
in bold
b Anxiety is reported as the sum of the participants who endorsed any of the
anxiety subcodes and also accounts for participants who reported “anxiety”
without noting a subcode
c The category of “other” was created to represent select symptoms reported
by 2 or fewer participants that were also not reported as most bothersome,
most clinically important, or an AE of specific interest
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The two TEAEs discussed most by physicians were
weight gain and reduced sexual desire or perform-
ance. According to the physicians, weight gain was
common and almost immediate, but in contrast to
patient opinion, it was not always attributed to
medication; rather, it was attributed to poor eating
habits that were exacerbated during hospitalization
or major depressive episode. The physicians believed
that the weight gain created a negative impact that
was generally more significant for women, but some-
times created a positive impact for individuals with
poor appetite associated with MDD, because it
helped achieve healthy body weight. Reduced sexual
desire or performance was reportedly mentioned
within the first visit following medication change or
initiation. The physicians commented that it was not
always due to AAP, and it was rare to see an im-
provement of this TEAE while on medication.
Patient and physician summary
A summary of frequently reported, bothersome, or clin-
ically important AAP TEAEs conveyed by patients and
psychiatrists is illustrated in Fig. 1. This figure shows
that patients with MDD and schizophrenia used similar
terms to describe their TEAEs and the most frequent
and bothersome TEAEs reported by patients were men-
tioned by the psychiatrists as well. One exception was
that the terminology and descriptions of some TEAEs
differed between patients and clinicians, such as that of
akathisia. Instead of using the clinical term, patients de-
scribed experiences consistent with akathisia, including
“very uncomfortable and shaking inside,” “can’t get com-
fortable,” “needing to move,” “can’t sit still,” “had to
fidget,” and “jumping out of my skin.” Many TEAEs that
were highly bothersome were also noted as frequently
occurring, including weight gain, low energy, somno-
lence, cognitive issues, and EPS. TEAEs considered
highly bothersome by patients and clinically significant
by psychiatrists included weight gain and cognitive is-
sues (MDD and schizophrenia) and EPS (schizophrenia),
although the results indicate that cognitive issues are
more bothersome than physicians think, especially for
MDD patients. In contrast, many other TEAEs were
considered clinically important by psychiatrists but not
by patients, including metabolic syndrome, reduced
sexual function, QT prolongation, hormonal changes,
akathisia, neutropenia, seizures, and hypotension. It
should be noted that some of these TEAEs (e.g., QT
prolongation, neutropenia) are not amenable to self-
reporting by the patient and therefore, should not ne-
cessarily be considered unimportant by the patient.
However, although the patients cannot self-report these
specific TEAEs, they were discussed as part of the ex-
haustive list.
Discussion
Newer, second generation (atypical) antipsychotics
demonstrate improved efficacy and reduced side effect
burden compared with older, first generation anti-
psychotic medications [11, 12]. However, a risk of
TEAEs, including weight gain, EPS, sexual dysfunction,
and somnolence remains [9, 16, 17]. This study sup-
ports these previous findings and sheds light on TEAE
perspectives and preferences that may impact treatment
decisions for patients with schizophrenia or MDD be-
ing treated with these newer agents. These differences
should be taken into account to improve the thera-
peutic alliance between patients and physicians.
This study used focus groups for MDD patients, inter-
views for schizophrenia patients, and focus groups for
physicians to form and rank an exhaustive list of TEAEs
to show that patients with MDD and schizophrenia gen-
erally used similar words to describe the TEAEs they
Table 4 Atypical antipsychotic AEs reported by physicians as
clinically important and/or bothersome









Metabolic syndrome a 4 (100) 4 (100) n/a
Weight gain 4 (100) 2 (50) 4 (100)
Reduced sexual desire
or performance
4 (100) 1 (25) 2 (50)
Neutropenia b 3 (75) 3 (75) 1 (25)
Hyperglycemia b 3 (75) 2 (50) 0
EPS b 3 (75) 1 (25) 2 (50)
Hyperlipidemia 3 (75) 1 (25) 0
Akathisia 3 (75) 0 2 (50)
QT prolongation b 2 (50) 2 (50) 0
Major medical (seizures) 2 (50) 1 (25) 1 (25)
Hormonal 2 (50) 0 2 (50)
Hypotension 2 (50) 0 1 (25)
Cognitive issues 2 (50) 0 1 (25)
Major medical (diabetes)
b
1 (25) 1 (25) 1 (25)
Hypertension 1 (25) 1 (25) 0
Low energy 1 (25) 0 1 (25)
Depressive symptoms 1 (25) 0 0
Flat/restricted affect 1 (25) 0 0
Somnolence/sedation 1 (25) 0 0
Abbreviations: AE adverse event, EPS extrapyramidal symptoms, QT time
between the start of the Q wave and the end of the T wave in the heart’s
electrical cycle
a Reported as “most clinically important” in the group setting but not the
individual task
b Reported as “most clinically important” in the group setting and in the
individual task
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were experiencing. TEAEs reported as bothersome
across both patient groups included cognitive issues,
weight gain and/or increased appetite, low energy, EPS,
and the need to sleep/excessive sleep/excessive sleepiness.
TEAEs considered more bothersome by patients with
schizophrenia were weight gain, low energy, EPS, mental
anxiety and increased positive symptoms, whereas TEAEs
considered more bothersome by patients with MDD were
cognitive issues, somnolence/sedation, and flat/restricted
affect. Patients’ and physicians’ perspectives did not align
as well as those across the two patient groups. TEAEs
considered most clinically important by psychiatrists in-
cluded metabolic syndrome, weight gain, neutropenia,
hyperglycemia, and QT prolongation; those considered
most bothersome to patients from physicians’ perspec-
tives included weight gain, reduced sexual desire or
performance, EPS, akathisia, and hormonal issues.
Some of the differences between the perspectives of pa-
tients and psychiatrists were related to clinical term
use. For example, differences in understanding of
akathisia may have been due to differences in termin-
ology as well as differences in description and/or ex-
perience, which may explain why clinicians saw it as
clinically important and patients did not list it as most
bothersome. In addition, due to patients’ tendency to
combine types of EPS, the TEAEs of tardive dyskinesia,
dystonia, and Parkinson symptoms were combined for
the purposes of this study. Interestingly, three of the
most frequent and bothersome TEAEs reported by pa-
tients (low energy, somnolence/sedation, and cognitive
issues) were not described by physicians as being clin-
ically important or most bothersome. This may reflect
the challenges that physicians have in measuring and
recording these events; but it may also reflect an as-
sumption by the physicians that these symptoms are
due to the disease while patients ascribe the adverse
events to the treatment. This study did not attempt to
tease this apart but this question would be useful for
further research in support of improving the thera-
peutic alliance.
The results described in this study provide better
understanding of the occurrence and burden of TEAEs
associated with AAP medications as reported by pa-
tients and physicians. It is also interesting to compare
the frequency and burden ratings from this study to
the adverse event profiles of the drugs as observed in
the clinical trials and described in the approved prod-
uct information (PI) sheets. A survey of the top five
product PIs as listed by the patients in this study (ris-
peridone, olanzapine, lurasidone, aripiprazole and que-
tiapine) reveals both similarities and differences. No































































































































































































































Fig. 1 Summary of Frequently Reported, Bothersome, or Clinically Important Adverse Events Reported by Patients and Physicians.a. EPS,
extrapyramidal symptoms; MDD, major depressive disorder; TEAE, treatment-emergent adverse event.a “Frequent” refers to the overall frequency of
report for either patient type or for psychiatrists and refers to TEAEs mentioned by ≥50% of patients or those described as “frequent” by psychiatrists;
“Bothersome” refers to the report of a TEAE as bothersome by ≥30% of either patient type or as “most” bothersome by ≥20% of either patient type and
for psychiatrists as “most bothersome” by 2 of the 4 psychiatrists; “Important” refers to TEAEs identified as “clinically important” by 2 of the 4 psychiatrists.
b In addition, the following AEs were listed as clinically important by ≥2 physicians: neutropenia, hyperglycemia, hyperlipidemia, QT prolongation,
seizures (major medical), hypotension, and metabolic syndrome
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section on Adverse Reactions with MDD or schizo-
phrenia. Akathisia is listed in four of the five PIs,
which is reflected in the common mention by psychia-
trists. Other frequent and burdensome AEs, such as
weight gain or increased appetite, somnolence, and
lethargy/fatigue are each mentioned in three of the
five PIs as a common adverse event. However, dizzi-
ness and constipation are also listed in three of five
PIs but are not mentioned as often by the patients or
physicians in this study. Conversely, the very common
and burdensome AE of cognitive issues is not men-
tioned in any PI, nor are sexual function changes. The
mismatch between labelling and patient and physician
experience further emphasizes the need to better incorp-
orate patient perspective into adverse event reporting and
evaluation.
Another way to look at efficacy and tolerability of
AAPs is head-to-head clinical trial analysis, as has been
shown in a recent mixed-treatment comparison analysis
that was used to directly compare the efficacy and toler-
ability of AAPs [27]. While useful, these types of trials
do not reveal how the TEAEs affect patients. To fully
understand AE burden in utilization of antipsychotics,
the patient perspective needs to be taken into account.
Patient attitudes toward antipsychotics are important for
adherence to and eventual outcome of the antipsychotic
treatment. Surveys of patient attitude toward antipsy-
chotics, including tolerability of TEAEs, have shown a
better attitude toward second-generation antipsy-
chotics compared with first-generation antipsychotics,
although the results are still debatable [28]. A toler-
ability index would facilitate the evaluation of TEAE
burden among patients and would contribute to the
process of prescribing appropriate antipsychotics to
patients with MDD and schizophrenia. The informa-
tion gained in the current study on patient perspec-
tives of TEAE burden will assist in the creation of a
tolerability index, which may facilitate appropriate
prescribing of AAP medications.
An important consideration based on this study is that
if the most burdensome side effects for patients can be
determined, physicians can better select the right treat-
ment from the choices available. A multiple treatment
meta-analysis of randomized, controlled schizophrenia
trials compared 15 antipsychotic drugs and placebo in
the acute treatment of schizophrenia and found that
whereas antipsychotics had small but robust differences
in efficacy, they differed substantially in side effects [12].
The findings challenged the routine classification of anti-
psychotics by first- and second-generation types (ie, typ-
ical and atypical types) and suggested that domain
hierarchies should be used to help clinicians adapt the
choice of an antipsychotic drug to the needs of individ-
ual patients [13]. The results of this study demonstrate
the variety of the individual needs of patients, and the
potential mismatch between patients’ and physicians’
perspectives. In future research, it will be interesting to
further examine sources of variability in patient and
physician perspective. For instance, there may be inter-
national differences in the perception of burden of these
common adverse events that should be carefully de-
scribed and taken into account in selection of medica-
tion in other settings.
This was a patient perspective study, and in addition to
the general limitations of a study based on patient reports,
it is important to recognize other study limitations. For
example, the sample size was small and limited to two
geographic locations in the US. A US sample was selected
in part because of the wider range of AAPs currently ap-
proved for the treatment of MDD in the US, and also be-
cause of the recent campaign by the FDA to include
patients’ perspectives in the overall benefit-risk profile for
treatment [18]. Therefore, the results may not be able to
be generalized to a larger or transnational patient or phys-
ician population. Further, patient reports proved insuffi-
cient for concluding valid results on certain queries. In
particular, TEAE onset was investigated because patients
are more likely to experience TEAEs early in treatment
that may or may not resolve as the patient continues with
the treatment. Unfortunately, onset was difficult to deter-
mine for most patients and varied greatly in the cases
where it was able to be determined. Finally, the data quan-
titation used a “top 3 box approach.” While this approach
enabled the intuitive comparison of perspectives across
small and varied sample sizes, this method can also cause
a loss of precision. Finally, although unlikely to have af-
fected the study outcomes, the study was funded by a
pharmaceutical company and the participating patients
and physicians received honoraria for their time.
Conclusion
The wide range of TEAEs that are both frequent and
bothersome and the variation in perceived burden
according to the diagnosis highlight the need for a tai-
lored TEAE-awareness approach when choosing an
AAP. Following feedback from both patients and psychi-
atrists, the following TEAEs would probably carry the
most weight for a tolerability index measure: weight gain
and/or increased appetite, low energy, somnolence/sed-
ation, cognitive issues, EPS, and reduced sexual desire or
performance. Other TEAEs that were considered clinic-
ally important by psychiatrists included abnormal test
results or blood values, cardiovascular issues, major
medical issues, hormonal changes, and akathisia. Infor-
mation gained in this study on TEAE burden associated
with AAP use will be helpful in the future development
of tools for assessing the overall tolerability of these
agents.
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